Mutational Spectra of Tamoxifen-Induced Mutations in the Livers of lacl Transgenic Rats

Environmental and Molecular Mutagenesis

Volumn 28, Issue 4, 1996, Pages 430-433

  Davies, Reginald ^a   Oreffo, Victor I C ^a   Bayliss, Stuart ^a   Dinh, Phuong Anh ^a   Lilley, Kathryn S ^a   White, Ian N H ^a   Smith, Lewis L ^a   Styles, Jerry A ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Big Blue; Gene; lacl; Mutation; Tamoxifen

Indexed keywords

ANIMALIA; BACTERIA (MICROORGANISMS);

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BACTERIAL PROTEIN; ESCHERICHIA COLI PROTEIN; LACI PROTEIN, BACTERIA; REPRESSOR PROTEIN; TAMOXIFEN;

ANIMAL; ARTICLE; DRUG EFFECT; FISCHER 344 RAT; GENETICS; LIVER; MALE; MUTATION; RAT; SINGLE STRAND CONFORMATION POLYMORPHISM; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTINEOPLASTIC AGENTS, HORMONAL; BACTERIAL PROTEINS; ESCHERICHIA COLI PROTEINS; LIVER; MALE; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RATS; RATS, INBRED F344; REPRESSOR PROTEINS; TAMOXIFEN;

EID: 0030345886     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2280(1996)28:4<430::AID-EM19>3.0.CO;2-G     Document Type: Article

References (23)

1. Carthew P, Martin EA, White INH, De Matteis F, Edwards RE, Dorman BM, Heydon RT, Smith LL (1995a): Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: Promotion by phenobarbital. Cancer Res 55:544-547.
2. 32P-postlabelling in three rat strains exposed to dietary tamoxifen: The relationship between cell proliferation and liver tumour formation. Carcinogenesis 16:1299-1304.
3. Chakravarti D, Pelling JC, Cavalieri EL, Rogan EG (1995): Relating aromatic hydrocarbon-induced DNA adducts and c-H-ras mutations in mouse skin papillomas: The role of apurinic sites. Proc Natl Acad Sci USA 92:10422-10426.
4. Cherpillod P, Amstad PA (1995): Benzo[a]pyrene-induced mutagenesis of p53 hot-spot codons 248 and 249 in hepatocytes. Mol Carcinogen 13:15-20.
5. Dycaico MJ, Provost GS, Kretz PL, Ransom SL, Moores JC, Short JM (1994): The use of shuttle vectors for mutation analysis in transgenic mice and rats. Mutat Res 307:461-478.
6. Fisher B (1996): Commentary on endometrial cancer deaths in tamoxifen-treated breast cancer patients. J Clin Oncol 14:1027-1039.
7. Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T (1993): Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res 53:3919-3924.
8. Han X, Liehr JG (1990): Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52:1360-1363.
9. Hard G, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi AR, Williams GM (1993): Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res 53:4534-4541.
10. Jordan VC (1992): Overview from the international conference on long term tamoxifen therapy for breast cancer. J Natl Cancer Inst 84:231-234.
11. Kohler SW, Provost GS, Fieck A, Kretz PL, Bullock WO, Sorge JA, Putman DL, Short JM (1991): Spectra of spontaneous and mutagen-induced mutations in the lacl gene in transgenic mice. Proc Natl Acad Sci USA 88:7958-7962.
12. Lehman TA, Harris CC (1994): Mutational spectra of protooncogenes and tumour suppressor genes: Clues in predicting cancer etiology. In "DNA Adducts: Identification and Biological Significance." IARC Scientific Publications 125, Lyon: IARC, pp 399-412.
13. Loeb LA, Preston BD (1986): Mutagenesis by apurinic/apyrimidinic sites. Annu Rev Genet 20:201-230.
14. 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen. Carcinogenesis 16:1651-1654.
15. Martin EA, Turtletaub KW, Heydon R, Davies A, White INH, Smith LL (1995b): Characterisation of tamoxifen induced DNA adducts formed in rat liver. Abstract 811. Toxicologist 15:152.
16. Osborne MR, Hewer A, Hardcastle IR, Carmichael PL, Phillips DH (1996): Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res 56:66-71.
17. Sargent LM, Dragan YP, Bahnub N., Wiley JE, Sattler C, Schroeder P, Sattler GL, Jordan VC, Pitot HC (1994): Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res 54:3357-3360.
18. Styles JA, Davies R, Martin EA, White INH, Smith LL (1996): Tamoxifen causes somatic gene mutations, DNA adducts and hyperplasia in the livers of Big Blue™ transgenic F344 rats. Abstract 823. Toxicologist 30:161.
19. Tucker MJ, Adam HK, Patterson JS (1984): Tamoxifen. In: Laurence DR, McLean AEM, Weatherall M (eds): "Safety Testing of New Drugs." New York: Academic Press, pp 125-161.
20. Ushijima T, Hosoya Y, Ochiai M, Kushida H, Wakabayashi K, Suzuki T, Hayashi M, Sofuni T, Sugimura T, Nagao M (1995a): Tissue-specific mutational spectra of MeIQ in the liver and bone marrow of lacl transgenic mice. Carcinogenesis 15:2805-2809.
21. Ushijima T, Hosoya Y, Suzuki T, Sofuni T, Sugimura T, Nagao M (1995b): A rapid method for detection of mutations in the lacl gene using PCR-single stranded conformational polymorphism analysis. Mutat Res 334:283-292.
22. Vancutsem PM, Lazarus P, Williams GM (1994): Frequency and specific mutations of the rat p53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 54:3864-3867.
23. White INH, De Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH (1993): Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats. DBA/ 2 and C57B1/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197-2203.